Catalyst Wire Dossier Catalyst Wire Dossier

REGN7999

· Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for REGN7999, covering 2024-07-24 to 2026-03-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body [Phase 2]

See pricing